Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week results from BE HEARD I&II
media
posted on 2025-07-01, 12:47 authored by Adis Journals on behalf of, Vivian Shi, John Ingram, Hadar Lev-Tov, Sylke Schneider-Burrus, Seth Forman, Martina Porter, Koremasa Hayama, Linnea Thorlacius, Jérémy Lambert, Tom Vaux, Bartosz Lukowski, Robert Rolleri, Jacek SzepietowskiArticle full text The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. The above Graphical Abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
